BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 18682687)

  • 1. EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1.
    Thomas SL; Zhong D; Zhou W; Malik S; Liotta D; Snyder JP; Hamel E; Giannakakou P
    Cell Cycle; 2008 Aug; 7(15):2409-17. PubMed ID: 18682687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties.
    Olivera A; Moore TW; Hu F; Brown AP; Sun A; Liotta DC; Snyder JP; Yoon Y; Shim H; Marcus AI; Miller AH; Pace TW
    Int Immunopharmacol; 2012 Feb; 12(2):368-77. PubMed ID: 22197802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin.
    Kasinski AL; Du Y; Thomas SL; Zhao J; Sun SY; Khuri FR; Wang CY; Shoji M; Sun A; Snyder JP; Liotta D; Fu H
    Mol Pharmacol; 2008 Sep; 74(3):654-61. PubMed ID: 18577686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin analog EF24 induces apoptosis via ROS-dependent mitochondrial dysfunction in human colorectal cancer cells.
    He G; Feng C; Vinothkumar R; Chen W; Dai X; Chen X; Ye Q; Qiu C; Zhou H; Wang Y; Liang G; Xie Y; Wu W
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1151-1161. PubMed ID: 27787644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The curcumin analog EF24 targets NF-κB and miRNA-21, and has potent anticancer activity in vitro and in vivo.
    Yang CH; Yue J; Sims M; Pfeffer LM
    PLoS One; 2013; 8(8):e71130. PubMed ID: 23940701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological Effects of EF24, a Curcumin Derivative, Alone or Combined with Mitotane in Adrenocortical Tumor Cell Lines.
    Bertazza L; Barollo S; Mari ME; Faccio I; Zorzan M; Redaelli M; Rubin B; Armanini D; Mian C; Pezzani R
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31212829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy.
    Thomas SL; Zhao J; Li Z; Lou B; Du Y; Purcell J; Snyder JP; Khuri FR; Liotta D; Fu H
    Biochem Pharmacol; 2010 Nov; 80(9):1309-16. PubMed ID: 20615389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.
    Carew JS; Esquivel JA; Espitia CM; Schultes CM; Mülbaier M; Lewis JD; Janssen B; Giles FJ; Nawrocki ST
    PLoS One; 2012; 7(1):e31120. PubMed ID: 22295124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies.
    Bisht S; Schlesinger M; Rupp A; Schubert R; Nolting J; Wenzel J; Holdenrieder S; Brossart P; Bendas G; Feldmann G
    J Nanobiotechnology; 2016 Jul; 14(1):57. PubMed ID: 27401816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple anticancer activities of EF24, a novel curcumin analog, on human ovarian carcinoma cells.
    Tan X; Sidell N; Mancini A; Huang RP; Shenming Wang ; Horowitz IR; Liotta DC; Taylor RN; Wieser F
    Reprod Sci; 2010 Oct; 17(10):931-40. PubMed ID: 20693500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function.
    Escuin D; Kline ER; Giannakakou P
    Cancer Res; 2005 Oct; 65(19):9021-8. PubMed ID: 16204076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-33b, upregulated by EF24, a curcumin analog, suppresses the epithelial-to-mesenchymal transition (EMT) and migratory potential of melanoma cells by targeting HMGA2.
    Zhang P; Bai H; Liu G; Wang H; Chen F; Zhang B; Zeng P; Wu C; Peng C; Huang C; Song Y; Song E
    Toxicol Lett; 2015 May; 234(3):151-61. PubMed ID: 25725129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microtubules regulate hypoxia-inducible factor-1α protein trafficking and activity: implications for taxane therapy.
    Carbonaro M; Escuin D; O'Brate A; Thadani-Mulero M; Giannakakou P
    J Biol Chem; 2012 Apr; 287(15):11859-69. PubMed ID: 22367210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analog.
    Liu H; Liang Y; Wang L; Tian L; Song R; Han T; Pan S; Liu L
    PLoS One; 2012; 7(10):e48075. PubMed ID: 23118928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M410, a combretastatin A4 analogue, disrupts microtubules and inhibits HIF-1α in human breast cancer cells.
    Yang H; Xia Q; Zou Y; Wang K; Jiang W; Cai Y
    Oncol Rep; 2015 Jul; 34(1):334-40. PubMed ID: 25976207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The curcumin analog EF24 is a novel senolytic agent.
    Li W; He Y; Zhang R; Zheng G; Zhou D
    Aging (Albany NY); 2019 Jan; 11(2):771-782. PubMed ID: 30694217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity.
    Subramaniam D; May R; Sureban SM; Lee KB; George R; Kuppusamy P; Ramanujam RP; Hideg K; Dieckgraefe BK; Houchen CW; Anant S
    Cancer Res; 2008 Mar; 68(6):1962-9. PubMed ID: 18339878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Curcumin Analog EF24 is Highly Active Against Chemotherapy- Resistant Melanoma Cells.
    He Y; Li W; Zhang J; Yang Y; Qian Y; Zhou D
    Curr Cancer Drug Targets; 2021; 21(7):608-618. PubMed ID: 33655859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition.
    Choi H; Chun YS; Kim SW; Kim MS; Park JW
    Mol Pharmacol; 2006 Nov; 70(5):1664-71. PubMed ID: 16880289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.